ArticleMolecular genetics & genomic medicine2019
miR-33a inhibits cell growth in renal cancer by downregulation of MDM4 expression.
Article in Molecular genetics & genomic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- Reduced Exosomal miR-22 Promotes Cisplatin Resistance and Migration in Non-Small Cell Lung Cancer Cells Through MDM4 Upregulation.OncoTargets and therapy · 2026Article
- Identification and validation of the biomarkers related to ferroptosis in calcium oxalate nephrolithiasis.Aging · 2024Article
- MDMX in Cancer: A Partner of p53 and a p53-Independent Effector.Biologics : targets & therapy · 2024Review
- MiR-33a targets FOSL1 and EN2 as a clinical prognostic marker for sarcopenia by glioma.Frontiers in genetics · 2022Article
- Machine learning algorithm-based identification and verification of characteristic genes in acute kidney injury.Frontiers in medicine · 2022Article
- LINC00974 sponges miR-33a to facilitate cell proliferation, invasion, and EMT of ovarian cancer through HMGB2 upregulation.Genetics and molecular biology · 2022Article
- Article
- Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.Journal of experimental & clinical cancer research : CR · 2021Review
- The roles and regulation of MDM2 and MDMX: it is not just about p53.Genes & development · 2021Review
- MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.American journal of cancer research · 2021Review
- LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.Cancer medicine · 2020Article
- Role of microRNA-33a in malignant cells.Oncology letters · 2020Review
- miR‑205 suppresses cell migration, invasion and EMT of colon cancer by targeting mouse double minute 4.Molecular medicine reports · 2020Article
- miR-33a inhibits cell growth in renal cancer by downregulation of MDM4 expression.Molecular genetics & genomic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-33a (miR-33a) plays the role of the tumor suppressor gene by regulating the expression level of downstream genes. However, the effects of miR-33a in renal cell cancer (RCC) remain unknown. Our study was designed to investigate the expression level and potential function of miR-33a in RCC.
methodsRT-qPCR was applied to measure the levels of miR-33a in RCC tissues and cell lines. Western blotting and luciferase reporter assay were used to detect the relationship between miR-33a and Mouse double minute 4 (MDM4) in RCC cells. CCK-8 and flow cytometry were applied to detected cell viability and cell cycle. Animal models and TUNEL assay were applied to detect the effect of miR-33a on the growth of RCC and cell apoptosis.
resultsWe found that the levels of miR-33a were significantly decreased in RCC tissues and cell lines. Moreover, the low expression of miR-33a in RCC patients indicated a shorter overall survival (OS). Notably, MDM4 as a direct target of miR-33a in RCC, the expression level of MDM4 was significantly increased in RCC cells group than the control group. Furthermore, miR-33a overexpression significantly inhibited RCC cells growth than the control group, while the inhibitory effects of miR-33a were reversed upon the overexpression of MDM4. Luciferase reporter assays showed that there was a direct interaction between miR-33a and 3' UTR of MDM4 mRNA. In vivo, tumor volumes and weight were significantly decreased in the transfected miR-33a mimics group than the control group.
conclusionTaken together, our study indicates that miR-33a inhibits RCC cell growth by targeting MDM4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.